Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter:
Abivax: Maintenance outcomes from the Phase 3 ABTECT study of obefazimod in ulcerative colitis.
Allogene Therapeutics: Interim analysis of the ALPHA3 study of cema-cel as a frontline consolidation treatment for B-cell lymphoma. A preview can be read here.Continue to STAT+ to read the full story…